MedTrace Logo

To Investigate the Effect of Esketamine Hydrochloride on Pulmonary Complications

NCT06467513 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2024-06-21

No results posted yet for this study

Summary

The objective of this study was to evaluate the effect of esketamine on intraoperative hemodynamics in patients with heart valve replacement and to mitigate postoperative pulmonary complications

Conditions

  • Heart Diseases
  • Heart Valve Diseases

Interventions

DRUG

Esketamine hydrochloride injection

The low dose esketamine hydrochloride group was given 0.2mg/kg at induction of anesthesia, the high dose esketamine hydrochloride group was given 0.4mg/kg at induction of anesthesia, and the blank control group was not given Esketamine hydrochloride injection at induction of anesthesia.

Sponsors & Collaborators

  • Zhang XIao Mei

    lead OTHER

Principal Investigators

  • Wei Chen · Staff member of Department of Anesthesiology, Affiliated Hospital of Zunyi Medical University

  • Haiying Wang · Director of anesthesiology Department, Affiliated Hospital of Zunyi Medical University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2025-05-31
Completion
2025-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06467513 on ClinicalTrials.gov